Gsa Capital Partners LLP Oncternal Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.83 - $17.8 $103,980 - $2.23 Million	-125,278 Reduced 78.16%	35,012 $31,000
Q2 2022 Aug 09, 2022	BUY	$0.7 - $1.56 $62,330 - $138,907	89,043 Added 124.98%	160,290 $178,000
Q1 2022 May 11, 2022	BUY	$1.37 - $2.43 $81,853 - $145,185	59,747 Added 519.54%	71,247 $99,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $26,105 - $50,484	11,500 New	11,500 $26,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $62.7M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.